spacer
home > pmps > spring 2007 > unmasking the blind of over-encapsulation
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Unmasking the Blind of Over-Encapsulation

Richard Shannon at Almac Clinical Services, assesses the impact of over-encapsulation in the clinical supplies industry

A study conducted by the Tufts Center for the Study of Drug Development estimated that the cost of bringing a novel compound to market is in excess of $800 million, so the need to prove superior efficacy and safety when compared to an already marketed product is of critical importance. When developing protocol designs, blinding or masking of clinical supplies is an integral part of many studies. This can help remove both investigator and patient bias due to the visibility of the marketed product, and can limit any potential placebo effect. One of the extensively used mechanisms available to sponsor companies to promote blinding is the over-encapsulation of tablets or capsules.

Over-encapsulation is now a widely accepted mechanism used throughout the clinical supplies industry, and while the process itself may appear relatively straightforward, packaging for clinical supplies is a complex process that is strictly controlled by good manufacturing practice (GMP). The principle of overencapsulation is simply the addition of a product or products to a hard gelatin capsule, which may or may not be backfilled with an inactive bulk agent or excipient. This process can be used for comparator products, investigational medicinal products (IMP) and/or placebos, providing an output of visually identical capsules for each product or strength, thus maintaining the blind and removing any potential bias.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Richard Shannon joined Almac Clinical Services (formerly Clinical Trial Services) in 1999 and has served in various business development functions during this time. He began his Almac career in Europe, before relocating to Almac, US, in 2001, where he gained valuable insight into the US clinical trial supply market and was integral in establishing a new business development team. Richard returned to Almac Europe in October 2005, and was appointed Head of Business Development (Europe). Prior to joining Almac, Richard was employed by MDS Harris (now MDS Pharmaservices) where he performed various clinical trial conduct roles. Richard holds a BSc (Hons) from Queen’s University, Belfast.
spacer
Richard Shannon
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Launches ADC ExpressTM Services to Accelerate Pre-clinical Conjugation Candidate Selection

• Provides rapid production of antibody drug conjugates (ADCs) for best candidate selection • Established platform technology to reliably scale target molecules • Reduces time to clinic through comprehensive ADC services from pre-clinical to commercial from a single source
More info >>

White Papers

Data Technology as a Catalyst for Growth in the Life Sciences

AIGENPULSE

The life sciences industry is changing at a rapid pace. The need to develop the next blockbuster is pushing current technologies and methodologies to the limit. Scientific advancement over the last decades was embossed with giant leaps in knowledge, however, the new reality is that smaller incremental gains need to be carved out with ever increasing investments. In order to survive, progress and prosper in this new reality, a holistic approach to getting the most of research data is crucial. In fact, it will likely be the difference of being in existence in 5-10 years or not. For those bold enough to step into an area they are unfamiliar with, huge rewards are waiting.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement